Inhibrx Biosciences, Inc.: 5%+ holders

As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Inhibrx Biosciences, Inc. The largest reported stake is Perceptive Advisors LLC's, at 9.99%. 11 filings are on record since October 17, 2025 (Schedule 13G/A, August 14, 2026).

Schonfeld Strategic Advisors LLC also filed stake reports on 5 other companies ↓

Sell to companies like Inhibrx Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-28 · Reporting person: Bank Of America Corp · Sole voting: 0 · Shared voting: 357,306 · Sole dispositive: 0 · Shared dispositive: 357,318 · SCHEDULE 13G/A, 2026-10-28
• Filing 2026-08-14 · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 1,489,443 · Sole dispositive: 0 · Shared dispositive: 1,489,443 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Viking Global Investors LP · Sole voting: 0 · Shared voting: 1,383,621 · Sole dispositive: 0 · Shared dispositive: 1,383,621 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Schonfeld Strategic Advisors LLC · Sole voting: 781,678 · Shared voting: 0 · Sole dispositive: 781,678 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
• Filed 2026-08-03 · Holder: Bank Of America Corp · Percent: 5.9% · SCHEDULE 13G

Inhibrx Biosciences, Inc. has 11 Schedule 13D or 13G filings on record since 2025-10-17. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Inhibrx Biosciences, Inc. and the warning signs.

See Inhibrx Biosciences, Inc.'s free Snapshot Watch Inhibrx Biosciences, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Inhibrx Biosciences, Inc. and the records around it.

Inhibrx Biosciences, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Schonfeld Strategic Advisors LLC also filed stake reports on 5 other companies: Cardinal Infrastructure Group Inc. (May 2026), Jiuzi Holdings, Inc. (Feb 2026), Fate Therapeutics, Inc. (Aug 2025)
• VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
• Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)

Want the whole picture on Inhibrx Biosciences, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Inhibrx Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Inhibrx Biosciences, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   11 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Inhibrx Biosciences, Inc. by CUSIP 45720N103 and gives its principal executive office as 11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA 92037 (SCHEDULE 13G/A, 2026-10-28).

What the percentages are based on

The percentages set forth herein are based on (i) 14,671,186 shares of Common Stock outstanding as of May 8, 2026, as reported by the Issuer in its quarterly report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (the "Commission") on May 14, 2026, and (ii) 259,692 shares of Common Stock that the Reporting Persons currently have the right to purchase upon exercise of the Warrants.Viking Global Investors LP, SCHEDULE 13G/A, 2026-08-14

Timeline

Swipe the table sideways to see every column.

Questions about who owns Inhibrx Biosciences, Inc.

Who owns Inhibrx Biosciences, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Inhibrx Biosciences, Inc.: Perceptive Advisors LLC (9.99%, Schedule 13G/A, filed 2026-08-14), Viking Global Investors LP (9.3%, Schedule 13G/A, filed 2026-08-14), Morgan Stanley (7.9%, Schedule 13G, filed 2026-02-11), Schonfeld Strategic Advisors LLC (5.33%, Schedule 13G, filed 2026-08-14) and BlackRock, Inc. (5.3%, Schedule 13G, filed 2026-01-21).

Who are the largest shareholders of Inhibrx Biosciences, Inc.?

By the share each holder's latest filing reports, the largest holders of Inhibrx Biosciences, Inc. on this page are Perceptive Advisors LLC (9.99%), Viking Global Investors LP (9.3%) and Morgan Stanley (7.9%).

When did Perceptive Advisors LLC buy into Inhibrx Biosciences, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Perceptive Advisors LLC on this page is the Schedule 13G/A, filed 2026-05-15, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Inhibrx Biosciences, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Inhibrx Biosciences, Inc. is mentioned again
• Find former Inhibrx Biosciences, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes